

<b>Symposium 13</b>	
<b>Best Oral Presentations</b>	
<u>OP-36</u>	<p><b>RISK FACTORS FOR KIDNEY SURVIVAL IN PATIENTS WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD)</b>            KATHRIN BURGMAIER 1 SAMUEL KILIAN 2 ANJA BÜSCHER 3 ISMAIL DURSUN 4 MARC FILA 5 IBRAHIM GOKCE 6 NAKYSA HOOMAN 7 MATKO MARLAIS 8 LAURA MASSELLA 9 ANTONIO MASTRANGELO 10 DJALILA MEKAHLI 11 LUKASZ OBRYCKI 12 LARISA PRIKHODINA 13 BRUNO RANCHIN 14 LUTZ T. WEBER 1 ELKE WÜHL 15 KATARZYNA ZACHWIEJA 16 JÖRG DÖTSCH 1 FRANZ SCHAEFER 15 MAX LIEBAU 17</p>
<u>OP-37</u>	<p><b>The potential of CTNS-mRNA based gene replacement therapy to treat nephropathic cystinosis</b>            TJESSA BONDUE 1 LAMBERTUS VAN DEN HEUVEL 1 RIK GIJSBERS 2 ROLAND BROCK 3 ELENA LEVTCHENKO 1</p>
<u>OP-38</u>	<p><b>Gitelman-Like Syndrome Caused by Pathogenic Variants in mtDNA</b>            SCHLINGMANN KARL 1 Viering Daan 2 Hureaux Marguerite 3 Nijenhuis Tom 4 Klaus Günter 5 Komhoff Martin 5 Beetz Rolf 6 Shenoy Mohan 7 Kleta Robert 8 Houillier Pascal 10 Konrad Martin 1 Vargas-Poussou Rosa 9 Knoers Nine 11 Bockenbauer Detlef 8 deBaaij Jeroen 2</p>
<u>OP-39</u>	<p><b>Efficacy of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children : the NEPHROVIR-3 randomized controlled trial</b>            CLAIRE DOSSIER 1 THERESA KWON 1 EMELINE CHAPELON 2 CYRIELLE PARMENTIER 3 AURELIEN GALERNE 4 ANNE CHACE 5 MARION CHEMINEE 6 SYLVIE NATHANSON 7 FOUAD MADHI 8 FERIELLE ZENKHRI 1 SEBASTIEN ROUGET 9 OLIVIA BOYER 10 CELIA NEKROUF 11 ALEXANDRA ROUSSEAU 11 JULIEN HOGAN 1</p>
<u>OP-40</u>	<p><b>mTOR-activating mutations in RRAGD cause kidney tubulopathy and cardiomyopathy syndrome</b>            SCHLINGMANN KARL 1 Jouret Francois 2 Shen Kuang 3 Dafinger Claudia 4 Houillier Pascal 5 Oh Jun 6 Godefroid Nathalie 7 Schermer Bernhard 8 Bergmann Carsten 9 Beck Bodo 10 Sabatini David 1 Liebau Max 4 Vargas-Poussou Rosa 11 Knoers Nine 12 de Baaij Jeroen 13 Konrad Martin 1</p>
<u>OP-41</u>	<p><b>Bone biomarkers in response to different dosing regimen of cholecalciferol therapy in children with chronic kidney disease</b>            NIVEDITA KAMATH 1 ARPANA IYENGAR 1 HANSA REDDY 1 JYOTI SHARMA 2 JYOTI SINGHAL 2 SUDHA EKAMBARAM 3 SUSAN UTHUP 4 SUMITHRA SELVAM 1 DAGMAR CHRISTIANE-FISCHER 5 ANJA RAHN 5 MANDY WAN 6 RUKSHANA SHROFF 6</p>
<u>OP-42</u>	<p><b>Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1 (PH1): a report on 3 cases</b>            ANNE-LAURE SELLIER-LECLERC 1 CHARLENE LEVI 1 CECILE ACQUAVIVA-BOURDAIN 1 STEPHANIE CLAVE 2 JUSTINE BACCHETTA 1</p>
<u>OP-43</u>	<p><b>First Interim Analysis of the International X-Linked Hypophosphataemia (XLH) Registry: Paediatric Population Baseline Characteristics</b>            DIETER HAFFNER 1 JONATHAN LIU 2 ANGELA WILLIAMS 2 SUE WOOD 2 ELENA LEVTCHENKO 3</p>
<u>OP-44</u>	<p><b>Deciphering the immunological mechanisms underlying pediatric Idiopathic Nephrotic Syndrome</b>            GIULIA CRICRI 1 LINDA BELLUCCI 2 STEFANIA BRUNO 3 FEDERICO CAICCI 4 STEFANO TUROLO 5 WILLIAM MORELLO 5 GIOVANNI MONTINI 5 FEDERICA COLLINO 1</p>
<u>OP-45</u>	<p><b>High phosphate load-induced proximal tubular injury is associated with activated Stat3/Kim-1 signaling and macrophage recruitment</b>            BEATRICE RICHTER 1 TAMAR KAPANADZE 2 NINA WEINGÄRTNER 1 STEFANIE WALTER 1 ISABEL VOGT 1 ANDREA GRUND 1 JESSICA SCHMITZ 3 JAN HINRICH BRÄSEN 3 FLORIAN P. LIMBOURG 2 DIETER HAFFNER 1 MAREN LEIFHEIT-NESTLER 1</p>